Corrigendum to “Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease” [Hum. Immunol. (2016) 35–40] (Human Immunology (2016) 77(1) (35–40), (S0198885915005133), (10.1016/j.humimm.2015.10.010));Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease

Human Immunology

Volumn 77, Issue 1, 2016, Pages 35-40

  Tatari Calderone, Zohreh ^a,b   Gordish Dressman, Heather ^a,b   Fasano, Ross ^a,b   Riggs, Michael ^c   Fortier, Catherine ^d   Campbell, Andrew D ^e   Charron, Dominique ^d   Gordeuk, Victor R ^f   Luban, Naomi L C ^a,b   Vukmanovic, Stanislav ^a,b   Tamouza, Ryad ^d  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c CATO RESEARCH LTD   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Alloimmunization; HLA DQB1; HLA DRB1; Red Blood Cell transfusion; Sickle cell disease

Indexed keywords

ALLOANTIBODY; GENOMIC DNA; HLA ANTIGEN CLASS 2; HLA DQ2 ANTIGEN; HLA DQ3 ANTIGEN; HLA DQ4 ANTIGEN; HLA DQ5 ANTIGEN; HLA DQ6 ANTIGEN; HLA DQ7 ANTIGEN; HLA DQ8 ANTIGEN; HLA DQ9 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; UNCLASSIFIED DRUG; ALLOANTIGEN; HLA DQ ANTIGEN; HLA-DQB1 ANTIGEN;

ADOLESCENT; ADULT; ALLOIMMUNITY; ALLOIMMUNIZATION; ANTIBODY DETECTION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; ERYTHROCYTE TRANSFUSION; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NULL ALLELE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SICKLE CELL; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; GENETIC ASSOCIATION STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; IMMUNIZATION; IMMUNOLOGY; METABOLISM; YOUNG ADULT;

ADOLESCENT; ANEMIA, SICKLE CELL; CHILD; ERYTHROCYTE TRANSFUSION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HLA-DQ BETA-CHAINS; HLA-DRB1 CHAINS; HUMANS; IMMUNIZATION; ISOANTIBODIES; ISOANTIGENS; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84950986583     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2020.08.004     Document Type: Erratum

References (51)

1. Adams R.J., McKie V.C., Hsu L., Files B., Vichinsky E., Pegelow C., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. 1998, 339:5-11.
2. Adams R.J., Brambilla D. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N. Engl. J. Med. 2005, 353:2769-2778.
3. Russell M.O., Goldberg H.I., Reis L., Friedman S., Slater R., Reivich M., et al. Transfusion therapy for cerebrovascular abnormalities in sickle cell disease. J. Pediatr. 1976, 88:382-387.
4. Orlina A.R., Unger P.J., Koshy M. Post-transfusion alloimmunization in patients with sickle cell disease. Am. J. Hematol. 1978, 5:101-106.
5. Piomelli S. Chronic transfusions in patients with sickle cell disease. Indications and problems. Am. J. Pediatr. Hematol./Oncol. 1985, 7:51-55.
6. Rosse W.F., Gallagher D., Kinney T.R., Castro O., Dosik H., Moohr J., et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood 1990, 76:1431-1437.
7. Aygun B., Padmanabhan S., Paley C., Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002, 42:37-43.
8. Tatari-Calderone Z., Minniti C.P., Kratovil T., Stojakovic M., Vollmer A., Barjaktarevic I., et al. Rs660 polymorphism in Ro52 (SSA1; TRIM21) is a marker for age-dependent tolerance induction and efficiency of alloimmunization in sickle cell disease. Mol. Immunol. 2009, 47:64-70.
9. Tatari-Calderone Z., Tamouza R., Le Bouder G.P., Dewan R., Luban N.L., Lasserre J., et al. The association of CD81 polymorphisms with alloimmunization in sickle cell disease. Clin. Dev. Immunol. 2013, 2013:937846.
10. Zimring J.C., Stowell S.R., Johnsen J.M., Hendrickson J.E. Effects of genetic, epigenetic, and environmental factors on alloimmunization to transfused antigens: current paradigms and future considerations. Transfus. Clin. Biol. 2012, 19:125-131.
11. Tatari-Calderone Z., Fasano R.M., Miles M.R., Pinto L.A., Luban N.L., Vukmanovic S. High multi-cytokine levels are not a predictive marker of alloimmunization in transfused sickle cell disease patients. Cytokine 2014, 68:59-64.
12. Hendrickson J.E., Hod E.A., Perry J.R., Ghosh S., Chappa P., Adisa O., et al. Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion 2012, 52:231-240.
13. Hannema S.E., Brand A., van Meurs A., Smiers F.J. Delayed hemolytic transfusion reaction with hyperhemolysis after first red blood cell transfusion in child with beta-thalassemia: challenges in treatment. Transfusion 2010, 50:429-432.
14. Yazdanbakhsh K., Ware R.E., Noizat-Pirenne F. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. Blood 2012, 120:528-537.
15. Natukunda B., Brand A., Schonewille H. Red blood cell alloimmunization from an African perspective. Curr. Opin. Hematol. 2010, 17:565-570.
16. Chadebech P., Habibi A., Nzouakou R., Bachir D., Meunier-Costes N., Bonin P., et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion 2009, 49:1785-1792.
17. Vichinsky E.P. Current issues with blood transfusions in sickle cell disease. Semin. Hematol. 2001, 38:14-22.
18. Urbaniak S.J. Alloimmunity to RhD in humans. Transfus. Clin. Biol. 2006, 13:19-22.
19. Hall A.M., Cairns L.S., Altmann D.M., Barker R.N., Urbaniak S.J. Immune responses and tolerance to the RhD blood group protein in HLA-transgenic mice. Blood 2005, 105:2175-2179.
20. Reviron D., Dettori I., Ferrera V., Legrand D., Touinssi M., Mercier P., et al. HLA-DRB1 alleles and Jk(a) immunization. Transfusion 2005, 45:956-959.
21. Chiaroni J., Dettori I., Ferrera V., Legrand D., Touinssi M., Mercier P., et al. HLA-DRB1 polymorphism is associated with Kell immunisation. Br. J. Haematol. 2006, 132:374-378.
22. Hoppe C., Klitz W., Vichinsky E., Styles L. HLA type and risk of alloimmunization in sickle cell disease. Am. J. Hematol. 2009, 84:462-464.
23. Noizat-Pirenne F., Tournamille C., Bierling P., Roudot-Thoraval F., Le Pennec P.Y., Rouger P., et al. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. Transfusion 2006, 46:1328-1333.
24. Westman P., Hashemi-Tavoularis S., Blanchette V., Kekomaki S., Laes M., Porcelijn L., et al. Maternal DRB1*1501, DQA1*0102, DQB1*0602 haplotype in fetomaternal alloimmunization against human platelet alloantigen HPA-6b (GPIIIa-Gln489). Tissue Antigens 1997, 50:113-118.
25. + T cells. Blood 2009, 113:3838-3844.
26. L'Abbe D., Tremblay L., Goldman M., Decary F., Chartrand P. Alloimmunization to platelet antigen HPA-1a (Zwa): association with HLA-DRw52a is not 100%. Transfus. Med. 1992, 2:251.
27. Paul R., Minniti C.P., Nouraie M., Luchtman-Jones L., Campbell A., Rana S., et al. Clinical correlates of acute pulmonary events in children and adolescents with sickle cell disease. Eur. J. Haematol. 2013, 91:62-68.
28. Marsh S.G. Nomenclature for factors of the HLA system, update December 2012. Tissue Antigens 2013, 81:253-257.
29. Robinson J., Halliwell J.A., McWilliam H., Lopez R., Parham P., Marsh S.G. The IMGT/HLA Database. Nucleic Acids Res. 2013, 41. D1222-7.
30. Chou S.T., Jackson T., Vege S., Smith-Whitley K., Friedman D.F., Westhoff C.M. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013, 122:1062-1071.
31. Alarif L., Castro O., Ofosu M., Dunston G., Scott R.B. HLA-B35 is associated with red cell alloimmunization in sickle cell disease. Clin. Immunol. Immunopathol. 1986, 38:178-183.
32. Scally S.W., Petersen J., Law S.C., Dudek N.L., Nel H.J., Loh K.L., et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J. Exp. Med. 2013, 210:2569-2582.
33. Terao C., Yano K., Ikari K., Furu M., Yamakawa N., Yoshida S., et al. A main contribution of DRB1*04:05 among shared epitope and involvement of 57th DRB1 amino acid in association with joint destruction in ACPA(+) RA. Arthritis Rheumatol. 2015.
34. + T-cell differentiation in to regulatory T cells. Eur. J. Immunol. 2014, 44:3429-3438.
35. Ho P.Y., Barton A., Worthington J., Plant D., Griffiths C.E., Young H.S., et al. Investigating the role of the HLA-Cw*06 and HLA-DRB1 genes in susceptibility to psoriatic arthritis: comparison with psoriasis and undifferentiated inflammatory arthritis. Ann. Rheum. Dis. 2008, 67:677-682.
36. Tamouza R., Neonato M.G., Busson M., Marzais F., Girot R., Labie D., et al. Infectious complications in sickle cell disease are influenced by HLA class II alleles. Hum. Immunol. 2002, 63:194-199.
37. Fernandez-Cavada-Pollo M.J., Alcala-Pena M.I., Vargas-Perez M.L., Vergara-Prieto E., Vallcorba-Gomez-Del Valle I., Melero-Ruiz J., et al. Celiac disease and HLA-DQ genotype: diagnosis of different genetic risk profiles related to the age in Badajoz, southwestern Spain. Rev. Esp. Enferm. Dig. 2013, 105:469-476.
38. van Lummel M., Duinkerken G., van Veelen P.A., de Ru A., Cordfunke R., Zaldumbide A., et al. Posttranslational modification of HLA-DQ binding islet autoantigens in type 1 diabetes. Diabetes 2014, 63:237-247.
39. Lie B.A., Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr. Opin. Immunol. 2005, 17:526-531.
40. Baschal E.E., Aly T.A., Jasinski J.M., Steck A.K., Noble J.A., Erlich H.A., et al. Defining multiple common "completely" conserved major histocompatibility complex SNP haplotypes. Clin. Immunol. 2009, 132:203-214.
41. de la Concha E.G., Cavanillas M.L., Cenit M.C., Urcelay E., Arroyo R., Fernandez O., et al. DRB1*03:01 haplotypes: differential contribution to multiple sclerosis risk and specific association with the presence of intrathecal IgM bands. PLoS One 2012, 7:e31018.
42. Bilbao J.R., Calvo B., Aransay A.M., Martin-Pagola A., Perez de Nanclares G., Aly T.A., et al. Conserved extended haplotypes discriminate HLA-DR3-homozygous Basque patients with type 1 diabetes mellitus and celiac disease. Genes Immun. 2006, 7:550-554.
43. Medrano L.M., Dema B., Lopez-Larios A., Maluenda C., Bodas A., Lopez-Palacios N., et al. HLA and celiac disease susceptibility: new genetic factors bring open questions about the HLA influence and gene-dosage effects. PLoS One 2012, 7:e48403.
44. Ma Z.J., Sun P., Guo G., Zhang R., Chen L.M. Association of the HLA-DQA1 and HLA-DQB1 Alleles in Type 2 Diabetes Mellitus and Diabetic Nephropathy in the Han Ethnicity of China. J. Diabetes Res. 2013, 2013:452537.
45. Alahgholi-Hajibehzad M., Yilmaz V., Gulsen-Parman Y., Aysal F., Oflazer P., Deymeer F., et al. Association of HLA-DRB1*14, -DRB1*16 and -DQB1*05 with MuSK-myasthenia gravis in patients from Turkey. Hum. Immunol. 2013, 74:1633-1635.
46. Baldwin T.A., Hogquist K.A., Jameson S.C. The fourth way? Harnessing aggressive tendencies in the thymus. J. Immunol. 2004, 173:6515-6520.
47. Bao W., Zhong H., Li X., Lee M.T., Schwartz J., Sheth S., et al. Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major. Am. J. Hematol. 2011, 86:1001-1006.
48. Vingert B., Tamagne M., Desmarets M., Pakdaman S., Elayeb R., Habibi A., et al. Partial dysfunction of Treg activation in sickle cell disease. Am. J. Hematol. 2014, 89:261-266.
49. Ottenhoff T.H., Walford C., Nishimura Y., Reddy N.B., Sasazuki T. HLA-DQ molecules and the control of Mycobacterium leprae-specific T cell nonresponsiveness in lepromatous leprosy patients. Eur. J. Immunol. 1990, 20:2347-2350.
50. Riley E.M., Morris-Jones S., Taylor-Robinson A.W., Holder A.A. Lymphoproliferative responses to a merozoite surface antigen of Plasmodium falciparum: preliminary evidence for seasonal activation of CD8+/HLA-DQ-restricted suppressor cells. Clin. Exp. Immunol. 1993, 94:64-67.
51. + T cells is receptor dependent and HLA-DQ restricted. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:2598-2602.